Note: Supplemental materials are not guaranteed with Rental or Used book purchases.
- ISBN: 9780824728878 | 0824728874
- Cover: Hardcover
- Copyright: 6/8/2006
Offering lower toxicity and higher accuracy than conventional therapies, this source offers illustrative coverage of this new method to treat tumors associated with brain, breast, lung, and neuroendocrine cancers. Accompanied by a CD offering color images, radiolabeling procedures, and tips on radiopharmceutical administration, this source will offer comprehensive and expert guidance on this burgeoning therapeutic technique.
Foreword | p. iii |
Preface | p. v |
Contributors | p. xiii |
Peptide Structure and Analysis | p. 1 |
Introduction | p. 1 |
Peptide Conformation and Structures | p. 3 |
Methodologies for Peptide Design | p. 5 |
Methodologies for Peptide Synthesis | p. 11 |
Methodologies for Peptide Modifications Toward the Obtainment of a Peptide-Based Radiopharmaceutical | p. 16 |
Spectroscopic Studies | p. 19 |
Biomolecular Three-Dimensional Structures from X-Ray and Nuclear Magnetic Resonance Techniques | p. 22 |
References | p. 26 |
Radiopeptide Targeting for Tumor Therapy: Peptide Receptor Distribution | p. 31 |
Introduction | p. 31 |
Which Tumors Express Which Peptide Receptor? | p. 31 |
Multireceptor Targeting | p. 37 |
References | p. 38 |
Developments of Radiolabeled Peptides | p. 41 |
Introduction | p. 41 |
Background | p. 46 |
Somatostatin Analogs | p. 48 |
Cholecystokinin-B/Gastrin | p. 56 |
Bombesin | p. 60 |
Alpha Melanocyte Stimulating Hormone | p. 65 |
[Alpha][subscript v][Beta subscript 3] Antagonists | p. 70 |
Conclusion | p. 75 |
References | p. 76 |
The Labeling of Peptides with Positron-Emitting Radionuclides: The Importance of PET in Cancer Diagnosis | p. 87 |
Introduction | p. 87 |
The Different Positron-Emitting Radioisotopes | p. 88 |
Labeling Reactions with [Beta superscript +] Emitters | p. 93 |
Overview of Positron-Labeled Peptide Families Useful in Cancer Diagnosis and Therapy: Current Status and Future Perspectives | p. 104 |
Conclusion | p. 112 |
References | p. 113 |
Radiolabeling Dota-Peptides with [superscript 90]Y and [superscript 177]Lu to a High Specific Activity | p. 119 |
Radiolabeling Dota-Peptides with [superscript 90]Y and [superscript 177]Lu to a High Specific Activity | p. 119 |
Conclusions | p. 123 |
References | p. 124 |
Peptide Receptor Radionuclide Therapy: Preclinical Findings | p. 127 |
Introduction | p. 127 |
Octreotide | p. 128 |
Octreotide Analogs | p. 130 |
Lanreotide | p. 134 |
RC-160 | p. 135 |
RGD-Octreotate | p. 136 |
Conclusion | p. 138 |
References | p. 138 |
Pathological Evaluation and Biochemical Characterization of Peptide Receptors Other Than Somatostatin Receptors as Potential Tumor Targets for Radionuclide Diagnosis and Therapy | p. 145 |
Introduction | p. 145 |
Methodological Aspects | p. 147 |
Biochemical and Functional Characterization of Peptide Receptors and Their Normal Distribution | p. 152 |
Assessing Peptide Receptor Expression in Human Tumors | p. 156 |
Co-expression of Peptide Receptors in Tumors: A New Challenge for the Pathologist | p. 159 |
Conclusive Remarks and Future Perspectives | p. 161 |
References | p. 162 |
Peptide Receptor Therapy with [superscript 90]Y-Dotatoc: The Emerging Experience in Chile | p. 173 |
Introduction | p. 173 |
Patient Population and Methods | p. 174 |
Results | p. 174 |
Selected Cases | p. 174 |
Conclusion | p. 178 |
References | p. 179 |
Therapeutic Potential of Radiolabeled Peptides: The Basel Experience | p. 181 |
PRRT with [superscript 90]Y-Dotatoc in Patients with Neuroendocrine Tumors and with Thyroid Cancer | p. 182 |
Locoregional PRRT with [superscript 90]Y-Dotatoc in Patients with Glioma | p. 201 |
Discussion | p. 206 |
References | p. 206 |
Somatostatin Receptor-Mediated Radionuclide Therapy for Cancer: Therapy with [superscript 90]Y-Dota-Lanreotide | p. 209 |
Summary | p. 209 |
Introduction | p. 210 |
Selection of Patients | p. 211 |
Preparation of [superscript 111]In-/[superscript 90]Y-Dota-Lanreotide | p. 212 |
Diagnostic and Dosimetric Evaluation | p. 212 |
Dose and Administration of [superscript 90]Y-Dota-Lanreotide | p. 213 |
Evaluation of Therapeutic Response | p. 214 |
Results | p. 214 |
Tumor Uptake of [superscript 111]In-Dota-Lanreotide Compared with Octreotide Derivates | p. 216 |
Drawbacks | p. 217 |
Conclusions | p. 218 |
Future Outlook | p. 218 |
References | p. 218 |
Receptor Radionuclide Therapy with [superscript 90]Y-[Dota[superscript 0]]-Tyr[superscript 3]-Octreotide ([superscript 90]Y-Dotatoc): The IEO Experience | p. 221 |
Introduction | p. 221 |
Safety Aspects | p. 223 |
Efficacy | p. 225 |
Conclusions | p. 230 |
References | p. 230 |
New Clinical Studies with [superscript 177]Lu-Labelled Somatostatin Analogs | p. 233 |
Perspective | p. 236 |
References | p. 237 |
Radiation Dosimetry Methods for Therapy | p. 239 |
Introduction | p. 239 |
Internal Dosimetry Methods | p. 241 |
Resources for Performing Calculations | p. 247 |
Progress in 3D Dosimetry and Treatment Planning | p. 251 |
Relating Observed Doses to Biological Effects | p. 253 |
References | p. 256 |
Dosimetry Applied to Peptide Radionuclide Receptor Therapy | p. 263 |
Introduction | p. 263 |
Radionuclides and Radiocompounds | p. 264 |
Methods for Pretherapy Dosimetry | p. 266 |
Dosimetric Results in PRRT Trials | p. 278 |
Physical and Radiobiological Factors Related to Kidney Damage 285 Practical Considerations and Conclusions | p. 292 |
References | p. 293 |
Further Reading | p. 299 |
Methods to Reduce Radiation Exposure to Personnel During Radiolabelling and Infusion | p. 301 |
Introduction | p. 301 |
Shielding Requirements | p. 303 |
Local Skin Dose | p. 303 |
Radiopharmaceutical Preparation: Radiation Protection in the Hot Lab | p. 304 |
Dose Calibrator | p. 308 |
Dose to Skin Due to Contamination | p. 308 |
Radiation Protection During the Infusion | p. 309 |
Systemic Infusion | p. 309 |
Locoregional Infusion | p. 309 |
Patient Hospitalization | p. 310 |
Conclusions and Recommendations | p. 312 |
References | p. 313 |
Regulatory Requirements for Therapy Trials | p. 315 |
Introduction | p. 315 |
Justification and Optimization in the Use of Ionizing Radiation for Medical Purposes | p. 317 |
Medical Trials with the Use of Ionizing Radiation | p. 318 |
Risk Categorization (Based on ICRP 62) | p. 320 |
References | p. 322 |
Pretargeted Peptide Delivery with Irreversible Antibody | p. 323 |
Introduction | p. 323 |
Evolution of Pretargeting Systems | p. 324 |
Irreversible Antibodies | p. 328 |
Pegylation | p. 330 |
Conclusions | p. 331 |
References | p. 333 |
Targeted Chemotherapy: New Approaches to Treatment of Various Cancers Based on Cytotoxic Analogs of Luteinizing Hormone-Releasing Hormone (LH-RH), Somatostatin and Bombesin | p. 337 |
Background | p. 337 |
Preclinical Studies with Cytotoxic Somatostatin Analog AN-238 | p. 339 |
Preclinical Studies with Cytotoxic Bombesin Analog AN-215 | p. 341 |
Clinical Remarks | p. 341 |
Conclusions | p. 342 |
References | p. 342 |
Index | p. 345 |
Table of Contents provided by Ingram. All Rights Reserved. |
What is included with this book?
The New copy of this book will include any supplemental materials advertised. Please check the title of the book to determine if it should include any access cards, study guides, lab manuals, CDs, etc.
The Used, Rental and eBook copies of this book are not guaranteed to include any supplemental materials. Typically, only the book itself is included. This is true even if the title states it includes any access cards, study guides, lab manuals, CDs, etc.